These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 26383125

  • 1. Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.
    Marchand P, Bazin MA, Pagniez F, Rivière G, Bodero L, Marhadour S, Nourrisson MR, Picot C, Ruchaud S, Bach S, Baratte B, Sauvain M, Pareja DC, Vaisberg AJ, Le Pape P.
    Eur J Med Chem; 2015 Oct 20; 103():381-95. PubMed ID: 26383125
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents.
    Marhadour S, Marchand P, Pagniez F, Bazin MA, Picot C, Lozach O, Ruchaud S, Antoine M, Meijer L, Rachidi N, Le Pape P.
    Eur J Med Chem; 2012 Dec 20; 58():543-56. PubMed ID: 23164660
    [Abstract] [Full Text] [Related]

  • 3. New 5-(nitroheteroaryl)-1,3,4-thiadiazols containing acyclic amines at C-2: synthesis and SAR study for their antileishmanial activity.
    Tahghighi A, Emami S, Razmi S, Rezazade Marznaki F, Kabudanian Ardestani S, Dastmalchi S, Kobarfard F, Shafiee A, Foroumadi A.
    J Enzyme Inhib Med Chem; 2013 Aug 20; 28(4):843-52. PubMed ID: 22651800
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, and in vitro biological evaluation of novel thiazolopyrimidine derivatives as antileishmanial compounds.
    Istanbullu H, Bayraktar G, Akbaba H, Cavus I, Coban G, Debelec Butuner B, Kilimcioglu AA, Ozbilgin A, Alptuzun V, Erciyas E.
    Arch Pharm (Weinheim); 2020 Aug 20; 353(8):e1900325. PubMed ID: 32484266
    [Abstract] [Full Text] [Related]

  • 5. Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.
    Castera-Ducros C, Paloque L, Verhaeghe P, Casanova M, Cantelli C, Hutter S, Tanguy F, Laget M, Remusat V, Cohen A, Crozet MD, Rathelot P, Azas N, Vanelle P.
    Bioorg Med Chem; 2013 Nov 15; 21(22):7155-64. PubMed ID: 24080103
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and in vitro anti-leishmanial activity of 1-[5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl]- and 1-[5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines.
    Behrouzi-Fardmoghadam M, Poorrajab F, Ardestani SK, Emami S, Shafiee A, Foroumadi A.
    Bioorg Med Chem; 2008 Apr 15; 16(8):4509-15. PubMed ID: 18321711
    [Abstract] [Full Text] [Related]

  • 7. Novel antileishmanial chalconoids: synthesis and biological activity of 1- or 3-(6-chloro-2H-chromen-3-yl)propen-1-ones.
    Nazarian Z, Emami S, Heydari S, Ardestani SK, Nakhjiri M, Poorrajab F, Shafiee A, Foroumadi A.
    Eur J Med Chem; 2010 Apr 15; 45(4):1424-9. PubMed ID: 20074836
    [Abstract] [Full Text] [Related]

  • 8. Antileishmanial potential of fused 5-(pyrazin-2-yl)-4H-1,2,4-triazole-3-thiols: Synthesis, biological evaluations and computational studies.
    Patil SR, Asrondkar A, Patil V, Sangshetti JN, Kalam Khan FA, Damale MG, Patil RH, Bobade AS, Shinde DB.
    Bioorg Med Chem Lett; 2017 Aug 15; 27(16):3845-3850. PubMed ID: 28693910
    [Abstract] [Full Text] [Related]

  • 9. 2-Amino-thiophene derivatives present antileishmanial activity mediated by apoptosis and immunomodulation in vitro.
    Rodrigues KA, Dias CN, Néris PL, Rocha Jda C, Scotti MT, Scotti L, Mascarenhas SR, Veras RC, de Medeiros IA, Keesen Tde S, de Oliveira TB, de Lima Mdo C, Balliano TL, de Aquino TM, de Moura RO, Mendonça Junior FJ, de Oliveira MR.
    Eur J Med Chem; 2015 Dec 01; 106():1-14. PubMed ID: 26513640
    [Abstract] [Full Text] [Related]

  • 10. Synthesis of N-(1-methyl-1H-indol-3-yl)methyleneamines and 3,3-diaryl-4-(1-methyl-1H-indol-3-yl)azetidin-2-ones as potential antileishmanial agents.
    Singh GS, Al-Kahraman YM, Mpadi D, Yasinzai M.
    Bioorg Med Chem Lett; 2012 Sep 01; 22(17):5704-6. PubMed ID: 22832310
    [Abstract] [Full Text] [Related]

  • 11. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
    Garamvölgyi R, Dobos J, Sipos A, Boros S, Illyés E, Baska F, Kékesi L, Szabadkai I, Szántai-Kis C, Kéri G, Őrfi L.
    Eur J Med Chem; 2016 Jan 27; 108():623-643. PubMed ID: 26724730
    [Abstract] [Full Text] [Related]

  • 12. Synthesis of substituted aryloxy alkyl and aryloxy aryl alkyl imidazoles as antileishmanial agents.
    Bhandari K, Srinivas N, Marrapu VK, Verma A, Srivastava S, Gupta S.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):291-3. PubMed ID: 19913413
    [Abstract] [Full Text] [Related]

  • 13. Activities of naphthylisoquinoline alkaloids and synthetic analogs against Leishmania major.
    Ponte-Sucre A, Faber JH, Gulder T, Kajahn I, Pedersen SE, Schultheis M, Bringmann G, Moll H.
    Antimicrob Agents Chemother; 2007 Jan 01; 51(1):188-94. PubMed ID: 17088484
    [Abstract] [Full Text] [Related]

  • 14. Repurposing azole antifungals into antileishmanials: Novel 3-triazolylflavanones with promising in vitro antileishmanial activity against Leishmania major.
    Keighobadi M, Emami S, Fakhar M, Shokri A, Mirzaei H, Hosseini Teshnizi S.
    Parasitol Int; 2019 Apr 01; 69():103-109. PubMed ID: 30582997
    [Abstract] [Full Text] [Related]

  • 15. Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.
    Mendoza-Martínez C, Galindo-Sevilla N, Correa-Basurto J, Ugalde-Saldivar VM, Rodríguez-Delgado RG, Hernández-Pineda J, Padierna-Mota C, Flores-Alamo M, Hernández-Luis F.
    Eur J Med Chem; 2015 Mar 06; 92():314-31. PubMed ID: 25576738
    [Abstract] [Full Text] [Related]

  • 16. New series of 3,5-disubstituted tetrahydro-2H-1,3,5-thiadiazine thione (THTT) derivatives: Synthesis and potent antileishmanial activity.
    Arshad N, Hashim J, Irfanullah, Minhas MA, Aslam J, Ashraf T, Hamid SZ, Iqbal T, Javed S.
    Bioorg Med Chem Lett; 2018 Oct 15; 28(19):3251-3254. PubMed ID: 30146096
    [Abstract] [Full Text] [Related]

  • 17. In vitro antileishmanial activity of novel azoles (3-imidazolylflavanones) against promastigote and amastigote stages of Leishmania major.
    Shokri A, Emami S, Fakhar M, Teshnizi SH, Keighobadi M.
    Acta Trop; 2017 Mar 15; 167():73-78. PubMed ID: 28017860
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and anticancer activity of oxindole derived imidazo[1,5-a]pyrazines.
    Kamal A, Ramakrishna G, Raju P, Rao AV, Viswanath A, Nayak VL, Ramakrishna S.
    Eur J Med Chem; 2011 Jun 15; 46(6):2427-35. PubMed ID: 21481986
    [Abstract] [Full Text] [Related]

  • 19. In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.
    Bazin MA, Cojean S, Pagniez F, Bernadat G, Cavé C, Ourliac-Garnier I, Nourrisson MR, Morgado C, Picot C, Leclercq O, Baratte B, Robert T, Späth GF, Rachidi N, Bach S, Loiseau PM, Le Pape P, Marchand P.
    Eur J Med Chem; 2021 Jan 15; 210():112956. PubMed ID: 33148491
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and antileishmanial activity of novel 5-(5-nitrofuran-2-y1)-1,3,4-thiadiazoles with piperazinyl-linked benzamidine substituents.
    Tahghighi A, Marznaki FR, Kobarfard F, Dastmalchi S, Mojarrad JS, Razmi S, Ardestani SK, Emami S, Shafiee A, Foroumadi A.
    Eur J Med Chem; 2011 Jun 15; 46(6):2602-8. PubMed ID: 21501907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.